DK1389100T3 - Hidtil ukendte fremgangsmåder til behandling og forebyggelse af smerte under anvendelse af stressaktiverede proteinkinaseinhibitorer - Google Patents

Hidtil ukendte fremgangsmåder til behandling og forebyggelse af smerte under anvendelse af stressaktiverede proteinkinaseinhibitorer

Info

Publication number
DK1389100T3
DK1389100T3 DK02769765T DK02769765T DK1389100T3 DK 1389100 T3 DK1389100 T3 DK 1389100T3 DK 02769765 T DK02769765 T DK 02769765T DK 02769765 T DK02769765 T DK 02769765T DK 1389100 T3 DK1389100 T3 DK 1389100T3
Authority
DK
Denmark
Prior art keywords
stress
treating
protein kinase
kinase inhibitors
activated protein
Prior art date
Application number
DK02769765T
Other languages
English (en)
Inventor
Lisa D Aimone
Robert L Hudkins
Mathew S Miller
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Application granted granted Critical
Publication of DK1389100T3 publication Critical patent/DK1389100T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK02769765T 2001-05-16 2002-05-16 Hidtil ukendte fremgangsmåder til behandling og forebyggelse af smerte under anvendelse af stressaktiverede proteinkinaseinhibitorer DK1389100T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29122701P 2001-05-16 2001-05-16
US10/146,680 US7018999B2 (en) 2001-05-16 2002-05-15 Methods for the treatment and prevention of pain
PCT/US2002/015667 WO2002092065A2 (en) 2001-05-16 2002-05-16 Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors

Publications (1)

Publication Number Publication Date
DK1389100T3 true DK1389100T3 (da) 2008-12-08

Family

ID=26844179

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02769765T DK1389100T3 (da) 2001-05-16 2002-05-16 Hidtil ukendte fremgangsmåder til behandling og forebyggelse af smerte under anvendelse af stressaktiverede proteinkinaseinhibitorer

Country Status (13)

Country Link
US (1) US7018999B2 (da)
EP (1) EP1389100B1 (da)
JP (1) JP2004534751A (da)
AR (1) AR035971A1 (da)
AT (1) ATE410201T1 (da)
AU (1) AU2002342715A1 (da)
CA (1) CA2447091C (da)
DE (1) DE60229233D1 (da)
DK (1) DK1389100T3 (da)
ES (1) ES2314101T3 (da)
HK (1) HK1062806A1 (da)
MX (1) MXPA03010451A (da)
WO (1) WO2002092065A2 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
US7169802B2 (en) * 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
AR074374A1 (es) 2008-11-19 2011-01-12 Cephalon Inc Formas de un compuesto de pirrolocarbazol fusionado, composiciones que las comprenden y su uso en el tratamiento de la angiogénesis y los tumores sólidos.

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1381031A (en) 1920-01-19 1921-06-07 Thompson James Dumping-wagon
US4923986A (en) 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
AU3064992A (en) 1991-11-08 1993-06-07 University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
US5621101A (en) 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5756494A (en) 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
ATE165097T1 (de) 1993-05-28 1998-05-15 Cephalon Inc Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen
US5534426A (en) 1993-07-19 1996-07-09 The Regents Of The University Of California Oncoprotein protein kinase
US6514745B1 (en) 1993-07-19 2003-02-04 The Regents Of The University Of California Oncoprotein protein kinase
US5468872A (en) 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
WO1995022331A1 (en) 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions
US5594009A (en) 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5705511A (en) 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US6046208A (en) 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
US5616724A (en) 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
BR9710693A (pt) 1996-06-25 2000-01-11 Cephalon Inc Uso de um derivado de k-252a para o tratamento do nervo central ou periférico e super produção de citoquinona.
CN1285836A (zh) 1997-12-31 2001-02-28 赛福伦公司 3′－差向异构的K－252a衍生物
ATE212552T1 (de) 1998-04-17 2002-02-15 Tufts College Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
GB9811624D0 (en) 1998-05-29 1998-07-29 Merck Sharp & Dohme Therapeutic use
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
CZ2001701A3 (cs) 1998-08-26 2002-04-17 Cephalon, Inc. Způsob identifikace sloučeniny, která pozměňuje aktivitu kinasových proteinů s násobnou vazbou
JP2002532503A (ja) 1998-12-17 2002-10-02 エフ．ホフマン−ラ ロシュ アーゲー プロテインキナーゼ阻害剤としての４，５−ピラジノオキシンドール
AU771599B2 (en) 1998-12-17 2004-03-25 F. Hoffmann-La Roche Ag 4- and 5-alkynyloxindoles and 4- and 5-alkenyloxindoles
EP1149093A1 (en) 1998-12-17 2001-10-31 F. Hoffmann-La Roche Ag 4-aryloxindoles as inhibitors of jnk protein kinases
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
AU4483000A (en) 1999-04-23 2000-11-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk)
AU5316900A (en) 1999-06-03 2000-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk)
ES2260033T3 (es) 1999-07-02 2006-11-01 Stuart A. Lipton Uso de los inhibidores p38 mapk en efermadades oftalmicas.
HUP0202319A3 (en) 1999-07-16 2004-12-28 Warner Lambert Co Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
SK3572002A3 (en) 1999-08-13 2002-07-02 Vertex Pharma Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
NZ517578A (en) 1999-08-19 2004-02-27 Signal Pharm Inc Pyrazoloanthrone and derivatives thereof as JNK inhibitors and their compositions
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
WO2001091749A1 (en) 2000-06-01 2001-12-06 Merck & Co., Inc. Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors
AU2002228911A1 (en) 2000-11-08 2002-05-21 The General Hospital Corporation Methods for inhibiting pain
CA2430539C (en) 2000-12-05 2010-07-13 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases

Also Published As

Publication number Publication date
ES2314101T3 (es) 2009-03-16
US20030087899A1 (en) 2003-05-08
CA2447091C (en) 2012-03-27
EP1389100A2 (en) 2004-02-18
CA2447091A1 (en) 2002-11-21
ATE410201T1 (de) 2008-10-15
DE60229233D1 (de) 2008-11-20
MXPA03010451A (es) 2004-05-05
AR035971A1 (es) 2004-07-28
HK1062806A1 (en) 2004-11-26
WO2002092065A3 (en) 2003-07-31
WO2002092065A2 (en) 2002-11-21
US7018999B2 (en) 2006-03-28
EP1389100B1 (en) 2008-10-08
JP2004534751A (ja) 2004-11-18
AU2002342715A1 (en) 2002-11-25

Similar Documents

Publication Publication Date Title
ATE414699T1 (de) Inhibitoren von tyrosinkinasen
NO20020635D0 (no) Proteinpolymeriseringsinhibitorer og fremgangsmåter for anvendelse
DE60214701D1 (de) Inhibitoren von c-jun-n-terminalen-kinasen (jnk) und anderen proteinkinasen
NO20033387L (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
NO20035604D0 (no) Skiferhydreringsinhiberingsmiddel og fremgangsmåte for anvendelse derav
IS7977A (is) Samsetningar og aðferð til samsettra meðferðar
NO20011964L (no) Brönnbehandlingsfluider og fremgangsmåter for anvendelse derav
NO20041582L (no) Antistoffinhibitorer av GDF-8 og anvendelse derav
DK1539224T3 (da) Antimikrobielt præparat og fremgangsmåde til anvendelse
DK1997809T3 (da) P38-inhibitorer og fremgangsmåder til anvendelse deraf
IS8037A (is) P38-hindrar og aðferðir til notkunar þeirra
DE50310980D1 (de) VERWENDUNG VON I kappa B-KINASE INHIBITOREN IN DER SCHMERZTHERAPIE
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
DK1590360T3 (da) Fremgangsmåde til fremstilling af inhibitorer af nukleosidphosphorylaser og nukleosidaser
NO20033429D0 (no) Fremgangsmåter for behandling av inflamatoriske og immunsykdommer ved anvendelse av inhibitorer av I-kappa-B kinase (IKK)
DK1432417T3 (da) Substituerede imidazolforbindelser og deres anvendelse til behandling af cancer
DK1589973T3 (da) Formulering og fremgangsmåder til behandling af thrombocytæmi
NO20033506D0 (no) Parasittdrepende preparater og fremgangsmåter for anvendelse
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
DK1389100T3 (da) Hidtil ukendte fremgangsmåder til behandling og forebyggelse af smerte under anvendelse af stressaktiverede proteinkinaseinhibitorer
DK1381620T3 (da) Hypersulfaterede disaccharider og fremgangsmåder til anvendelse af samme til behandling af inflammationer
DK1244662T3 (da) Pyridazinoquinolinderivater og fremgangsmåde til behandling af smerter
DK1307761T3 (da) Fremgangsmåde til retningsbestemmelse og bestemmelsesapparat
DK1379242T3 (da) Fremgangsmåde til behandling af cancer og sammensætninger til anvendelse derved
NO20011900L (no) Brönnbehandlingsfluider og fremgangsmåter for anvendelse derav